Innovative, centralised, multidisciplinary medicines optimisation clinic for PCSK9 inhibitors

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) are an important but underutilised option to help optimise lipid management. We developed a new service to improve patient access to these medicines in line with National Institute for Health and Care Excellence recommend...

Descripción completa

Detalles Bibliográficos
Autores principales: Khatib, Rani, Khan, Mutiba, Barrowcliff, Abigail, Ikongo, Eunice, Burton, Claire, Mansfield, Michael, Hall, Alistair
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Cardiac Risk Factors and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991064/
https://www.ncbi.nlm.nih.gov/pubmed/35393352
http://dx.doi.org/10.1136/openhrt-2021-001931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8991064/
https://www.ncbi.nlm.nih.gov/pubmed/35393352
http://dx.doi.org/10.1136/openhrt-2021-001931

Ejemplares similares